Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.

UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.

In this week's EuroBiotech Report, Vicarius raises $22 million, GSK jilts Ionis, CellAct lands a $250 million deal and more. 

In our EuroBiotech roundup this week, Nicox raises €26 million, Vectura strikes deal with Dynavax and Kiadis secures debt financing.

The cash tees up Atreca to pick a clinical candidate derived from a platform that has attracted the interest of a who’s who of Big Pharma players.

The collaborators hope to learn about the role Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein.

Regulators stand accused of waving through drugs on the basis of slight data and then failing to ensure postapproval trials validate the decision.

Takeda's R&D shake-up continues to rumble on, with the Japanese drugmaker signing a wide-ranging deal that will see it work closely with researchers…

The biotech plans to use the cash to hustle cancer drugs licensed from Bristol-Myers and Tesaro through late-phase trials in its home nation of China.